Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$8.31 USD
-0.28 (-3.26%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $8.30 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.31 USD
-0.28 (-3.26%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $8.30 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Zacks News
Atara Reports Initial Data for Multiple Sclerosis Candidate
by Zacks Equity Research
Atara (ATRA) announces initial ATA188 phase I safety results for patients with progressive MS.
Company News For Jan 4, 2019
by Zacks Equity Research
Companies in the news are: BMY, CELG, DAL, TRCO and ATRA
Atara Biotherapeutics (ATRA) in Focus: Stock Moves 6.9% Higher
by Zacks Equity Research
Atara Biotherapeutics (ATRA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Is a Beat in the Cards for Celldex (CLDX) in Q4 Earnings?
by Zacks Equity Research
With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on immuno-oncology pipeline.
What's in Store for Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Epizyme is expected to provide updates on the development of its pipeline candidates during Q4 earnings call.
What's in the Cards for Immune Design (IMDZ) in Q4 Earnings?
by Zacks Equity Research
We expect Immune Design (IMDZ) to shed light on the progression of the trails on pipeline candidates when it releases fourth-quarter earnings results on Mar 6.
What's in Store for Intrexon (XON) This Earnings Season?
by Zacks Equity Research
Investor focus are likely to remain on Intrexon's (XON) performance along with other developmental updates during the quarterly call.
Madrigal (MDGL) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Madrigal (MDGL) has no approved product in its portfolio. So, investors' complete focus on fourth-quarter earnings call will be revolving around the company's lead pipeline candidate, MGL-3196.
What's in the Cards for Puma (PBYI) This Earnings Season?
by Zacks Equity Research
Contrary to nominal sales generated by Puma's (PBYI) only marketed drug Nerlynx last quarter, post its launch in August 2017, the candidate is likely to fetch higher revenues in Q4.
Is a Beat in Store for Adverum (ADVM) This Earnings Season?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) will report its fourth-quarter results in early March. Investors focus is expected to be on pipeline updates.
Is a Beat in Store for Horizon Pharma (HZNP) in Q4 Earnings?
by Zacks Equity Research
On Horizon Pharma's (HZNP) fourth-quarter 2017 earnings call, investors focus will be on the performance of its business units and key products.
What's in the Cards for Merrimack (MACK) in Q4 Earnings?
by Zacks Equity Research
Investors are likely to remain focused on Merrimack's (MACK) pipeline updates when it reports Q4 numbers, early next month.
What's in Store for Endocyte (ECYT) This Earnings Season?
by Zacks Equity Research
Endocyte (ECTY) is expected to provide updates on its pipeline candidates EC1169 and EC2629 during the fourth quarter 2017 earnings call on Feb 26.
What's in the Cards for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earns $70 million in milestone and license payments from several drug companies. Spinraza witnesses strong fourth quarter as announced by Biogen in its earnings release.
Jazz Pharmaceuticals (JAZZ) Q4 Earnings: What to Expect?
by Zacks Equity Research
In Q4, we expect investors' focus on Xyrem's performance, Jazz Pharmaceuticals' (JAZZ) lead product for excessive daytime sleepiness. Also, hopes will be pinned on the company's pipeline progress.
Will ACADIA (ACAD) Disappoint Investors in Q4 Earnings?
by Zacks Equity Research
ACADIA (ACAD) is expected to provide further update on the progress of Nuplazid when it reports Q4 results on Feb 27.
5 Best-Performing Stocks of the Top ETF of January
by Sweta Killa
Inside the top performing stocks of the top biotech ETF of January.
Zacks.com highlights: Arbor Realty Trust, Simpson Manufacturing and Atara Biotherapeutics
by Zacks Equity Research
Zacks.com highlights: Arbor Realty Trust, Simpson Manufacturing and Atara Biotherapeutics
3 Stocks in Focus on New Analyst Coverage
by Zacks Equity Research
Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.